Cardiol Therapeutics Inc. (CRDL.TO)
Cardiol Therapeutics Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Oakville, ON, CA. The stock last traded at $2.06, down 2.37% on the session, giving a market capitalisation of $237.5M. Its beta of 0.47 implies it has historically moved less than the broad market.
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Cardiol Therapeutics Inc. is most often compared with the following Healthcare names: